In contrast, GLP-1 RA use was associated with an increased risk of malignant melanoma (HR, 1.31; 95% CI, 1.01–1.70), while no statistically significant increase was observed for breast cancer (HR, 1.04; 95% CI, 0.94–1.15) or thyroid cancer (HR, 1.09; 95% CI, 0.88–1.34). This evidence concerns the gene GLP1R and melanoma.